The role of MTHFR and RFC1 polymorphisms on toxicity and outcome of adult patients with hematological malignancies treated with high-dose methotrexate followed by leucovorin rescue

Cancer Chemotherapy and Pharmacology

Volumn 69, Issue 3, 2012, Pages 691-696

  Chiusolo, Patrizia ^a   Giammarco, Sabrina ^a   Bellesi, Silvia ^a   Metafuni, Elisabetta ^a   Piccirillo, Nicola ^a   De Ritis, Daniela ^a   Marietti, Sara ^a   Federica, Sorà ^a   Laurenti, Luca ^a   Fianchi, Luana ^a   Hohaus, Stefan ^a   Giuseppe, Leone ^a   Sica, Simona ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

High dose methotrexate; Lymphoproliferative diseases; MTHFR polymorphisms; Outcome; RFC1 polymorphisms; Toxicity

Indexed keywords

ADENINE; CYTOSINE; FOLINIC ACID; GENOMIC DNA; GUANINE; HOMOCYSTEINE; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; THYMINE;

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE GENE; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGE; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; BLOOD TOXICITY; BURKITT LYMPHOMA; CANCER PATIENT; CANCER SURVIVAL; COHORT ANALYSIS; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG MEGADOSE; FEMALE; GENE; GENETIC VARIABILITY; GENOTYPE; HEMATOLOGIC MALIGNANCY; HETEROZYGOTE; HOMOCYSTEINE BLOOD LEVEL; HOMOZYGOTE; HUMAN; LIVER TOXICITY; LUNG EMBOLISM; LYMPHOBLASTOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIMARY CENTRAL NERVOUS SYSTEM LYMPHOMA; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; REDUCED FOLATE CARRIER GENE; SIDE EFFECT; WILD TYPE;

ADOLESCENT; ADULT; AGED; ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COHORT STUDIES; DISEASE-FREE SURVIVAL; HEMATOLOGIC NEOPLASMS; HUMANS; KAPLAN-MEIER ESTIMATE; LEUCOVORIN; MALE; METHOTREXATE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MIDDLE AGED; POLYMORPHISM, GENETIC; REDUCED FOLATE CARRIER PROTEIN; YOUNG ADULT;

EID: 84859737779     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-011-1751-4     Document Type: Article

References (35)

1. Blasco H, Senecal D, Le Gouge A et al (2010) Influence of methotrexate exposure on outcome in patients treated with MBVP chemotherapy for primary central nervous system lymphoma. Br J Clin Pharmacol 70(3):367-375
2. Yustein JT, Dang CV (2007) Biology and treatment of Burkitt's lymphoma. Curr Opin in Hematol 14(4):375-381 (Pubitemid 46842812)
3. Magrath I, Adde M, Shad A, Venzon D et al (1996) Adults and children with small non-cleaved-cell lymphoma have a similar excellent outcome when treated with the same chemotherapy regimen. J Clin Oncol 14(3):925-934 (Pubitemid 26085538)
4. Bailey LB, Gregory JF (1999) Polymorphisms of methylenetetrahydrofolate reductase and other enzymes: metabolic significance, risks and impact on folate requirement. J Nutr 129(5): 919-922 (Pubitemid 29214439)
5. Ueland PM, Hustad S, Schneede J et al (2001) Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 22(4):195-201 (Pubitemid 32244306)
6. Chango A, Emery-Fillon N, de Courcy GP et al (2000) A polymorphism (80G?A) in the reduced folate carrier gene and its associations with folate status and homocysteinemia. Mol Genet Metab 70(4):310-315
7. De Marco P, Calevo MG, Moroni A et al (2003) Reduced folate carrier polymorphism (80A?G) and neural tube defects. Eur J Hum Genet 11(3):245-252 (Pubitemid 36511863)
8. Shaw GM, Lammer EJ, Zhu H et al (2002) Maternal periconceptional vitamin use, genetic variation of infant reduced folate carrier (A80G), and risk of spina bifida. Am J Med Genet 108(1):1-6 (Pubitemid 34101374)
9. Pei L, Liu J, Zhang Y et al (2009) Association of reduced folate carrier gene polymorphism and maternal folic acid use with neural tube defects. Am J Med Genet B Neuropsychiatr Genet 150B(6):874-878
10. Shang Y, Zhao H, Niu B et al (2008) Correlation of polymorphism of MTHFRs and RFC-1 genes with neural tube defects in China. Birth Defects Res A Clin Mol Teratol 82(1):3-7 (Pubitemid 351157084)
11. Weisberg I, Tran P, Christensen B et al (1998) A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Mol Genet Metab 64(3):169-172 (Pubitemid 28453294)
12. Frosst P, Blom HJ, Milos R et al (1995) A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 10(1):111-113
13. Trotti A, Byhardt R, Stetz J et al (2000) Common toxicity criteria: version 2.0. An improved reference for grading the acute effect of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys 47(1):13-47 (Pubitemid 30179675)
14. Chiusolo P, Reddiconto G, Cimino G et al (2004) Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population. Haematologica 89(2):139-144 (Pubitemid 38796487)
15. Aplenc R, Thompson J, Han P et al (2005) Methylenetetrahydrofolate reductase polymorphisms and therapy response in pediatric acute lymphoblastic leukemia. Cancer Res 65(6): 2482-2487 (Pubitemid 40490161)
16. Krajinovic M, Lemieux-Blanchard E et al (2004) Role of polymorphisms in MTHFR and MTHFD1 genes in the outcome of childhood acute lymphoblastic leukemia. Pharmacogenomics J 4(1):66-72 (Pubitemid 38256607)
17. Krajinovic M, Lamothe S, Labuda D et al (2004) Role of MTHFR genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Blood 103(1):252-257 (Pubitemid 38029946)
18. Kim HN, Kim YK, Lee IK et al (2009) Association between polymorphisms of folate-metabolizing enzymes and hematological malignancies. Leuk Res 33(1):82-87
19. Chiusolo P, Reddiconto G, Cimino G et al (2004) Methylenetetrahydrofolate reductase genotypes do not play a role in acute lymphoblastic leukemia pathogenesis in the Italian population. Haematologica 89(2):139-144 (Pubitemid 38796487)
20. Ongaro A, De Mattei M, Della Porta MG et al (2009) Gene polymorphisms in folate metabolizing enzymes in adult acute lymphoblastic leukemia: effects on methotrexate-related toxicity and survival. Haematologica 94(10):1391-1398
21. Liu JX, Chen JP, Tan W et al (2008) Association between MTHFR gene polymorphisms and toxicity of HDMTX chemotherapy in acute lymphocytic leukemia. Zhongguo Shi Yan Xue Ye Xue Za Zhi 16(3):488-492
22. Kantar M, Kosova B, Cetingul N et al (2009) Methylenetetrahydrofolate reductase C677T and A1298C gene polymorphisms and therapy-related toxicity in children treated for acute lymphoblastic leukemia and non-Hodgkin lymphoma. Leuk Lymphoma 50(6):912-917
23. Toffoli G, Russo A, Innocenti F et al (2003) Effect of methylenetetrahydrofolate reductase 677C→T polymorphism on toxicity and homocysteine plasma level after chronic methotrexate treatment of ovarian cancer patients. Int J Cancer 103(3):294-299 (Pubitemid 36076421)
24. Urano W, Taniguchi A, Yamanaka H et al (2002) Polymorphisms in the methylenetetrahydrofolate reductase gene were associated with both the efficacy and the toxicity of methotrexate used for the treatment of rheumatoid arthritis, as evidenced by single locus and haplotype analyses. Pharmacogenetics 12(3):183-190 (Pubitemid 34596782)
25. Shimasaki N, Mori T, Samejima H et al (2006) Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 28(2):64-68
26. Seidemann K, Book M, Zimmermann M et al (2006) MTHFR 677 (C→T) polymorphism is not relevant for prognosis or therapy-associated toxicity in pediatric NHL: results from 484 patients of multicenter trial NHL-BFM 95. Ann Hematol 85(5): 291-300 (Pubitemid 43732651)
27. Chiusolo P, Reddiconto G, Farina G et al (2007) MTHFR polymorphisms'influence on outcome and toxicity in acute lymphoblastic leukemia patients. Leuk Res 31(12):1669-1674 (Pubitemid 350051399)
28. Huang L, Tissing WJ, de Jonge R et al (2008) Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 22(9):1798-1800
29. de Jonge R, Hooijberg JH, van Zelst BD et al (2005) Effect of polymorphisms in folate-related genes on in vitro methotrexate sensitivity in pediatric acute lymphoblastic leukemia. Blood 106(2):717-720 (Pubitemid 40981271)
30. Jansen G, Mauritz R, Drori S et al (1998) A structurally altered human reduced folate carrier with increased folic acid transport mediates a novel mechanism of antifolate resistance. J Biol Chem 273(46):30189-30198 (Pubitemid 28545482)
31. Whetstine JR, Gifford AJ, Witt T et al (2001) Single nucleotide polymorphisms in the human reduced folate carrier: characterization of a high-frequency G/A variant at position 80 and transport properties of the His(27) and Arg(27) carriers. Clin Cancer Res 7(11):3416-3422 (Pubitemid 33069975)
32. Dervieux T, Furst D, Lein DO et al (2004) Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 50(9):2766-2774 (Pubitemid 39209513)
33. Rocha JC, Cheng C, Liu W et al (2005) Pharmacogenetics of outcome in children with acute lymphoblastic leukemia. Blood 105(12):4752-4758 (Pubitemid 40807300)
34. Lavardière C, Chiasson S, Costea I et al (2002) Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and out come of childhood acute lymphoblastic leukemia. Blood 100(10):3832-3834 (Pubitemid 35303961)
35. Ashton LJ, Gifford AJ, Kwan E et al (2009) Reduced folate carrier and methylenetetrahydrofolate reductase gene polymorphisms: associations with clinical outcome in childhood acute lymphoblastic leukemia. Leukemia 23(7):1348-1351